Nav: Home

Two Baylor College of Medicine faculty members named to National Academy of Medicine

October 25, 2016

Dr. Malcolm Brenner, founding director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, and Dr. Cheryl Walker, founding director of the Center for Precision Environmental Health at Baylor, both renowned leaders in their respective fields, were elected to membership in the National Academy of Medicine.

Brenner, professor of medicine, pediatrics - hematology/oncology and molecular and human genetics at Baylor, is a clinician-scientist who pioneered basic and clinical research focused on use of gene transfer to augment the immune response to tumors. His contributions have led to the development of genetically modified T cells that can safely and effectively target cancer tumors.

Walker, professor of molecular and cellular biology and of medicine at Baylor, joined the College in August to develop the Center for Precision Environmental Health to better understand causes of disease through research at the intersection of genetics, environmental health and computational biology. Her work focuses on finding the mechanisms by which environmental exposures early in life "reprogram" the epigenome of developing cells, tissues and organs to change how they function.

"This is a well-deserved honor for Dr. Brenner and Dr. Walker," said Dr. Paul Klotman, president, CEO and executive dean of Baylor College of Medicine. "They both are leaders in their fields who have contributed groundbreaking findings, and this is an important honor for them and for the College."

Brenner holds the Fayez Sarofim Chair at Baylor and, in addition to the Center for Cell and Gene Therapy, also is a member of the Stem Cell and Regenerative Medicine Center, Texas Children's Cancer and Hematology Centers and the Dan L Duncan Comprehensive Cancer Center at Baylor.

Brenner's clinical research interests span many aspects of stem cell transplantation, using genetic manipulation of cultured cells to obtain therapeutic effects. Efforts in his laboratory to analyze the cell of origin when relapse occurs in patients with acute myelogenous leukemia led Brenner's team to be the first to label autologous bone marrow cells genetically after purging, prior to being reintroduced to the patient. He is now studying the use of gene-modified T lymphocytes for prevention and treatment of Hodgkin and non-Hodgkin lymphoma, lung cancer, nasopharyngeal cancer and neuroblastoma, and has developed and clinically tested safety switches to reduce the toxicity of these cells.

He served as editor-in-chief of Molecular Therapy and a former president of the American Society for Gene and Cell Therapy (ASGCT) and the International Society for Cell Therapy. He has won many awards for his work, including the ASGCT Outstanding Achievement, the American Society of Hematology Mentor award and the Pioneer Award from the peer-reviewed journal Human Gene Therapy in recognition of his scientific achievements and leadership in the field.

"I'm honored to have been elected to the Academy, and I am fortunate indeed to have worked with so many outstanding colleagues at Baylor, Texas Children's and Houston Methodist, since the work I do is truly 'team science,'" Brenner said.

Walker is a member of the Dan L Duncan Comprehensive Cancer Center at Baylor. Some of Walker's major research accomplishments include identifying tumor suppressor genes as the target for chemical carcinogens, creating an animal model for the most frequent gynecologic tumor of women, elucidating pathways by which environmental exposures reprogram the epigenome and discovering a new linkage between the epigenome and the cytoskeleton with her recent publication in Cell reporting the discovery of a chromatin remodeler that also remodels the cell's cytoskeleton.

Among her numerous awards and recognitions are the Cozzarelli Prize in Biological Sciences from the National Academy of Sciences and the Society of Toxicology Leading Edge in Basic Science Award. She has been a named Fellow with the Academy of Toxicological Sciences and the American Association for the Advancement of Sciences. She also is a past-president of the Society of Toxicology and Women in Cancer Research of the American Association for Cancer Research.

"I have many colleagues who I greatly admire and respect in the National Academy," Walker said. "It is such an honor to now join their ranks."

The two are among 70 new members and 9 international members named to the Academy today. Baylor now has 15 members in the National Academy of Medicine, formerly the Institute of Medicine.

Brenner and Walker join the following group of distinguished scientists from Baylor in the National Academy of Medicine:

Dr. Bobby R. Alford
Dr. Arthur L. Beaudet
Dr. Dennis M. Bier
Dr. William R. Brinkley
Dr. William T. Butler
Dr. C. Thomas Caskey
Dr. Mary K. Estes
Dr. Richard A. Gibbs
Dr. Peter J. Hotez
Dr. Brendan Lee
Dr. James R. Lupski
Dr. Bert W. O'Malley
Dr. Huda Y. Zoghbi

The Academy was established in 1970 under the charter of the National Academy of Sciences to advise the nation on medical and health issues.
-end-


Baylor College of Medicine

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...